Perspective Therapeutics rises as experimental cancer drug shows promise

Perspective Therapeutics

20/04/2026 11:18

** Shares of biotech firm Perspective Therapeutics CATX.A rise 3.3% to $4.34 premarket

** Company says its experimental targeted radiation drug [212Pb]VMT-α-NET showed encouraging results in an early-stage trial in patients with advanced neuroendocrine tumors, a rare cancer that forms in hormone-making cells

** Company says in one dose group, 43% of patients saw tumors shrink, with some showing further improvement since earlier data

** The treatment was generally well-tolerated, with no serious kidney damage or severe blood disorders linked to the drug - CATX

** Company plans to share more data later this year and prepare for talks with regulators in 2026

** As of last close, shares up ~53% this year

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))